Dr. Green on Treatment Regimens for Patients With Multiple Myeloma in Early Relapse

Video

Michael Green, MD, Northern California Oncologist, discusses his preferred treatment regimens for patients with multiple myeloma in early relapse.

Michael Green, MD, Northern California Oncologist, discusses his preferred treatment regimens for patients with multiple myeloma in early relapse.

As multiple myeloma is a heterogenous disease, there is no standard regimen for patients in early relapse. If a patient does experience early relapse, Green individualizes the regimen to the patient based on the patient’s disease characteristics. Additionally, a physician must consider whether a patient has renal insufficiency or compromise to their kidneys, Green says. Choosing a treatment regimen also depends on whether a patient has liver disease or is experiencing neuropathy, as well as their functional abilities.

Sequencing is another factor to be mindful of, explains Green. Since there are many options for patients, it is important to keep in mind what a patient may need down the line. A physician has to be cognizant of what they use now because it will impact what is available for the patient in the future, concludes Green.

Related Videos
Saad Z. Usmani, MD, MBA, FACP, FASCO
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Don S. Dizon, MD
Rohan Garje, MD
Sarah E. S. Leary, MD, MS, attending physician, medical director, Pediatric Brain Tumor Program, Seattle Children’s Hospital; professor, Department of Pediatrics, University of Washington School of Medicine
Marc J. Braunstein, MD, PhD
Samer A. Srour, MB ChB, MS
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD